CMPS:NASDAQ
Compass Pathways PLC
$8.38
arrow_downward
-0.71%(-0.060) 1 日
$8.59
arrow_upward
+2.51% (+0.21)today立会前
終了: 4月29日, 16:00:01 GMT-4 · USD
search
すべての記号
1 日
5 日
1 か月
6 か月
年初来
1 年
5 年
最大
| 記号 | 価格 | 変化 | 変化率 |
|---|
insights_autoCMPS の上位の分析情報を生成しています...
始値
$8.45
高値
$8.57
安値
$8.25
時価総額
11.31億
平均出来高
376.18万
取引量
1.60万
52 週高値
$10.21
52 週安値
$2.25
EPS
-$3.08
ベータ版
2.01
発行済株式数
1.35億
従業員数
156
ニュース記事
ウェブの情報から
プロフィール
Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin, is currently in phase 3 clinical trials for treatment-resistant depression. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration. It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine.
Compass Pathways is the largest company in the psychedelic medicine industry and, in 2020, was the first psychedelic medicine company to be listed on the NASDAQ. It has faced criticism for patenting psychedelic drugs and even certain psilocybin mushroom species. In October 2024, after the FDA rejected Lykos Therapeutics's MDMA for post-traumatic stress disorder New Drug Application, Compass Pathways said that it would lay off 30% of its workforce and narrow its research focus.
Compass Pathways has entered partnerships with several independent psychedelic academic scientists, including Jason Wallach, Hamilton Morris, and Adam Halberstadt among others, to develop novel psychedelic drugs for potential medical use. Wikipedia
Compass Pathways PLC について